Cellex
Also known as: porcine brain sialic-acid peptide preparation
A Russian/Belarusian porcine-brain-derived sialic-acid peptide preparation used clinically for neurological indications, similar in architecture to Cerebrolysin but with a distinct compositional and clinical positioning.
Cellex is a Russian/Belarusian porcine-brain sialic-acid peptide preparation used clinically for neurological indications; similar architecture to Cerebrolysin with distinct compositional positioning.
Evidence tier: B — clinical evidence (trials or approved use in some jurisdictions)
- Category
- Neuroprotection
- Half-life
- Multi-component preparation with varied pharmacokinetics
Section 1
Overview
Cellex is a Russian/Belarusian porcine-brain-derived peptide preparation manufactured by controlled proteolytic digestion of purified porcine brain tissue with additional sialic-acid components. Its architecture parallels Cerebrolysin's multi-component preparation approach — a complex mixture of low-molecular-weight peptides, free amino acids, and other bioactive components rather than a single defined molecule — but with distinct compositional standardisation and clinical positioning within Russian and Belarusian medical practice.
The compound is used clinically in the Russian Federation and some CIS countries for stroke recovery, cognitive impairment, and traumatic brain injury indications, providing a multi-decade clinical-use safety database within those jurisdictions. It is included on this reference to complete the multi-component-preparation neuroprotective peptide family alongside Cerebrolysin and Cortexin.
Cellex is not licensed in the UK or under EMA-centralised authorisation. Direct clinical use is not available through UK healthcare channels. The compound is included here for reference completeness on the Russian/CIS peptide-preparation clinical landscape.
Section 2
Discovery & History
- Developed in the Russian/Belarusian pharmaceutical development framework as a porcine-brain peptide preparation with distinct compositional and clinical positioning from Cerebrolysin.
- Approved for clinical use in the Russian Federation and some CIS countries for neurological indications.
- Substantial Russian-language clinical-trial and clinical-experience literature covering stroke recovery, cognitive impairment, and traumatic brain injury indications.
- Not approved for clinical use under UK MHRA, EMA-centralised, or FDA regulatory authorisation.
- Not commercially available through mainstream UK research-chemical channels; sourcing is generally limited to Russian/CIS pharmaceutical import routes.
Section 3
Mechanism of Action
- 1Multi-component neurotrophic factor mimicry — the preparation contains fragments that reproduce aspects of BDNF, NGF, GDNF, and CNTF signalling without being any single neurotrophin, similar to Cerebrolysin's architecture.
- 2Sialic-acid-containing components providing distinctive mechanistic angles including modulation of cell-surface glycoprotein interactions and neural cell adhesion molecule (NCAM) signalling.
- 3Anti-apoptotic effects in ischaemic and traumatic neuronal injury models via preservation of mitochondrial function and reduced caspase-3 activation.
- 4Modulation of microglial activation phenotype and reduction of neuroinflammatory cytokine expression in CNS injury models.
- 5Reported effects on adult hippocampal neurogenesis in some preclinical work, providing a cognitive-plasticity mechanism angle.
- 6Effects on synaptic protein expression and dendritic morphology in preclinical models, extending the neuroprotective mechanism into synaptic-plasticity contexts.
- 7Antioxidant effects at the neuronal level via multiple bioactive components contributing to the endogenous antioxidant defence pathway.
Section 4
Researched Benefits
Findings reported in the published preclinical and clinical literature. Effects in research contexts do not constitute claims of therapeutic benefit in humans.
- 1Approved clinical use in the Russian Federation and some CIS countries with substantial clinical-experience database.
- 2Multi-component preparation architecture providing pleiotropic mechanistic effects on multiple pathways simultaneously.
- 3Distinctive sialic-acid-containing composition providing mechanistic angles unshared by Cerebrolysin.
- 4Reported effects in stroke recovery, cognitive impairment, and TBI indications in the Russian clinical literature.
- 5Well-tolerated in the reported clinical experience across paediatric, adult, and elderly populations.
- 6Complements Cerebrolysin and Cortexin coverage on this reference by extending the Russian/CIS multi-component-preparation neuroprotective family.
Section 5
Theoretical Dosing & Protocols
| Route | Dosage | Frequency | Duration |
|---|---|---|---|
| Subcutaneous injection (clinical use in approving jurisdictions) | 0.1-0.2 mg per dose in the licensed clinical protocols | Once or twice daily during a treatment cycle | Cycles of 10 days, sometimes repeated after intervals |
Note: Not approved or prescribed in the UK; this information is provided for educational reference only.
Section 6
Administration Routes
- Subcutaneous injection — the standard clinical route in the Russian/CIS approved use.
- Intramuscular administration in some clinical protocols.
- Oral administration is not viable for a peptide-based preparation.
Section 7
Safety Profile
Commonly reported
- · Generally well-tolerated in the Russian/CIS clinical use.
- · Mild injection-site reactions with subcutaneous administration.
- · Occasional hypersensitivity reactions — local rash.
- · Occasional mild transient headache during a course.
Rare / theoretical
- · Anaphylactic reactions to the porcine-derived preparation, as with any animal-protein biologic.
- · Theoretical infectious-disease considerations associated with animal-derived biologics.
- · Long-term safety data outside the Russian/CIS clinical experience is limited.
- · Rare cardiovascular events reported at very low frequency.
Contraindications
- · Not licensed for human use in the UK.
- · Known hypersensitivity to porcine-derived proteins.
- · Pregnancy and lactation (per labelling in approving jurisdictions).
- · Active severe autoimmune disease — theoretical contraindication.
Section 8
UK & EU Regulatory Context
United Kingdom
Not a licensed medicine in the UK. Used in Russian and Belarusian clinical practice.
European Union
Not approved by the EMA. Approved in the Russian Federation and some CIS countries.
Section 9
Clinical Studies Summary
Cellex in post-stroke cognitive recovery
Russian clinical research in post-stroke rehabilitation populations reporting improvements in cognitive-endpoint measures and functional-recovery outcomes with adjunct Cellex versus standard-care controls. Provides the primary licensed-indication evidence base for the compound in stroke-recovery contexts.
Cellex mechanism characterisation
Characterisation studies describing Cellex's multi-component composition and the distinctive sialic-acid-containing bioactive components that differentiate its mechanism from Cerebrolysin. Provides the architectural framework for interpreting the compound's positioning within the Russian/CIS neuropeptide-preparation family.
Cellex in paediatric neurological indications
Russian and Belarusian clinical research applications of Cellex in paediatric neurological indications including perinatal CNS injury and developmental delays. Extends the licensed-indication evidence base into paediatric contexts parallel to Cortexin's broader paediatric positioning.
Section 10
Frequently Asked Questions
Section 10a
Practical Research Guidance
Cycle guidance
Reconstitution & storage
UK sourcing notes
Section 11
Sourcing for Laboratory Research
Sourcing Cellex for laboratory research
Researchers in the United Kingdom and elsewhere typically obtain Cellex from specialist research-chemical suppliers. Purity, third-party testing, and supplier transparency are the principal differentiators worth evaluating before placing an order. The two suppliers below are commonly referenced in UK research contexts.
Reminder: research peptides are sold strictly for in vitro and preclinical laboratory purposes. Importation or supply for human consumption is not permitted under UK medicines legislation.